Novocure added to ‘TAP Underperform’ list at Evercore ISI

Evercore ISI analyst Vijay Kumar is adding Novocure to the firm’s "TAP Underperform" list, citing the view that in the short-term the stock is pricing in "an overly optimistic" outcome for the LUNAR NSCLC readout. Kumar maintains an Underperform rating and $42 price target on Novocure shares.